troglitazone has been researched along with HELLP Syndrome in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
HELLP Syndrome: A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruebner, M | 1 |
| Langbein, M | 1 |
| Strissel, PL | 1 |
| Henke, C | 1 |
| Schmidt, D | 1 |
| Goecke, TW | 1 |
| Faschingbauer, F | 1 |
| Schild, RL | 1 |
| Beckmann, MW | 1 |
| Strick, R | 1 |
1 other study available for troglitazone and HELLP Syndrome
| Article | Year |
|---|---|
Regulation of the human endogenous retroviral Syncytin-1 and cell-cell fusion by the nuclear hormone receptors PPARγ/RXRα in placentogenesis.
Topics: Alitretinoin; Cell Fusion; Cell Line; Chromans; Cyclic AMP-Dependent Protein Kinases; Endogenous Ret | 2012 |